Brief: Akeso Announces First Patient Dosed In Phase I Trial Of Personalized mRNA Vaccine AK154 as Monotherapy or in Combination with Cadonilimab or Ivonescimab
10/11/2025 11:43
Nov 10 (Reuters) - Akeso Inc 9926.HK: AKESO ANNOUNCES FIRST PATIENT DOSED IN PHASE I TRIAL OF PERSONALIZED MRNA VACCINE AK154 AS MONOTHERAPY OR IN COMBINATION WITH CADONILIMAB OR IVONESCIMAB FOR ADJUVANT TREATMENT OF PANCREATIC CANCER Source text: ID:nPn9FPsy4a Further company coverage: 9926.HK ((reuters.briefs@thomsonreuters.com;))
Recent news on Akeso
See all newsBrief: Akeso Announces Summit Therapeutics And Ecog-Acrin Cancer Research Group Enter Into Phase Ii/Iii Clinical Trial Collaboration To Evaluate Ivonescimab In First-Line Biliary Tract Cancer
Factbox: Major drugmakers turn to China for licensing deals
HK-listed Akeso drops most in nearly three months on discounted share sale
Brief: Akeso To Place 20 Million New Shares At HK$97.76 Per Share
Factbox: Major drugmakers turn to China for licensing deals